PubMed · 11959607
Human immunodeficiency virus (HIV) Type 1 reverse transcriptase resistance mutations in hepatitis B virus (HBV)-HIV-coinfected patients treated for HBV chronic infection once daily with 10 milligrams of adefovir dipivoxil combined with lamivudine.
Abstract
Adefovir dipivoxil (ADV) at a suboptimal concentration for human immunodeficiency virus type 1 (HIV-1) (10 mg once daily) can be used to treat hepatitis B virus (HBV) infection in HIV-1-HBV-coinfected patients and does not, even in the case of uncontrolled HIV-1 replication, select for either ADV mutations at codons 65 and 70 or any other particular HIV-1 reverse transcriptase resistance profile.
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Constance Delaugerre, Anne-Geneviève Marcelin, Vincent Thibault, Gilles Peytavin, Tony Bombled, Marie-Valérie Bochet, Christine Katlama, Yves Benhamou, Vincent Calvez. 2002. Human immunodeficiency virus (HIV) Type 1 reverse transcriptase resistance mutations in hepatitis B virus (HBV)-HIV-coinfected patients treated for HBV chronic infection once daily with 10 milligrams of adefovir dipivoxil combined with lamivudine.. https://doi.org/10.1128/aac.46.5.1586-1588.2002
Cite the original work for its findings. Save a collection to share your selection of sources.